DUX4 and facioscapulohumeral muscular dystrophy: This is because the treatments were designed to specifically address the leaky DUX4 level, or they were applied shortly after switching on DUX4 expression, which is less relevant for FSHD patients who suffer from chronic DUX4 pathogenesis.